Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 TRACON and Ambrx Enter Development Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

TRACON and Ambrx Enter Development Agreement

The partnership resolves around the commercialization and development of TRC105 (carotuximab) in China

By: Betsy Louda

, Contract Pharma

TRACON Pharmaceuticals has entered into a licensing agreement with Ambrx for the development and commercialization of TRACON’s proprietary endoglin antibody, TRC105 (carotuximab), in China.

 

The transaction grants Ambrx the exclusive rights to develop and commercialize TRC105 in all indications in China and Taiwan. TRACON will receive an upfront payment of $3 million, and is eligible to receive development and regulatory milestones of up to $10.5 million, and commercial sales milestones of up to $130 million. TRACON is also eligible to receive tiered royalties from the high single digits to low teens on net sales of TRC105 in the Ambrx territories.

 

 “We are excited to expand the development and commercialization opportunities for TRC105 into the Chinese market with a strong partner. The Ambrx management team has a strong track record of drug development in China and are backed by a top-tier syndicate of investors,” said Charles Theuer, M.D., Ph.D., president and chief executive officer of TRACON. 

 

Ambrx intends to file an initial CTA with the Chinese Food and Drug Administration (CFDA) in 2018.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters